Citation Impact
Citing Papers
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Gain-of-function p53R172H mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy
2021
Reading the glyco-code: New approaches to studying protein–carbohydrate interactions
2022 StandoutNobel
How chemokines organize the tumour microenvironment
2023
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Organoid Models of Tumor Immunology
2020
Delivery technologies for cancer immunotherapy
2019 Standout
Preparing Medical Imaging Data for Machine Learning
2020 Standout
Measuring the multifaceted roles of mucin-domain glycoproteins in cancer
2022 StandoutNobel
Neutrophil diversity and plasticity in tumour progression and therapy
2020
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
2018
Consistency and Efficiency of CT Analysis of Metastatic Disease: Semiautomated Lesion Management Application Within a PACS
2013
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Therapeutic cancer vaccines
2015
Works of Fatima Karzai being referenced
A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening
2018
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
2019
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
2019
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
2020
A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC).
2012
A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.
2018
A phase I study of TRC105 (Anti-CD105 [endoglin] antibody) in metastatic castration resistant prostate cancer (mCRPC).
2012
Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
2017